These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The genetic signatures of pediatric high-grade glioma: no longer a one-act play. Diaz AK; Baker SJ Semin Radiat Oncol; 2014 Oct; 24(4):240-7. PubMed ID: 25219808 [TBL] [Abstract][Full Text] [Related]
9. Mutations in chromatin machinery and pediatric high-grade glioma. Lulla RR; Saratsis AM; Hashizume R Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386 [TBL] [Abstract][Full Text] [Related]
11. Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas. Herting CJ; Chen Z; Pitter KL; Szulzewsky F; Kaffes I; Kaluzova M; Park JC; Cimino PJ; Brennan C; Wang B; Hambardzumyan D Glia; 2017 Dec; 65(12):1914-1926. PubMed ID: 28836293 [TBL] [Abstract][Full Text] [Related]
12. Mouse models of glioma. Stylli SS; Luwor RB; Ware TM; Tan F; Kaye AH J Clin Neurosci; 2015 Apr; 22(4):619-26. PubMed ID: 25698543 [TBL] [Abstract][Full Text] [Related]
13. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Venkatesh HS; Tam LT; Woo PJ; Lennon J; Nagaraja S; Gillespie SM; Ni J; Duveau DY; Morris PJ; Zhao JJ; Thomas CJ; Monje M Nature; 2017 Sep; 549(7673):533-537. PubMed ID: 28959975 [TBL] [Abstract][Full Text] [Related]
14. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. Sturm D; Pfister SM; Jones DTW J Clin Oncol; 2017 Jul; 35(21):2370-2377. PubMed ID: 28640698 [TBL] [Abstract][Full Text] [Related]
15. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. Paugh BS; Qu C; Jones C; Liu Z; Adamowicz-Brice M; Zhang J; Bax DA; Coyle B; Barrow J; Hargrave D; Lowe J; Gajjar A; Zhao W; Broniscer A; Ellison DW; Grundy RG; Baker SJ J Clin Oncol; 2010 Jun; 28(18):3061-8. PubMed ID: 20479398 [TBL] [Abstract][Full Text] [Related]
16. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Westphal M; Lamszus K Nat Rev Neurosci; 2011 Aug; 12(9):495-508. PubMed ID: 21811295 [TBL] [Abstract][Full Text] [Related]
17. Cell of origin determines tumor phenotype in an oncogenic Ras/p53 knockout transgenic model of high-grade glioma. Ghazi SO; Stark M; Zhao Z; Mobley BC; Munden A; Hover L; Abel TW J Neuropathol Exp Neurol; 2012 Aug; 71(8):729-40. PubMed ID: 22805776 [TBL] [Abstract][Full Text] [Related]
18. Differential expression of microRNA-210 in gliomas of variable cell origin and correlation between increased expression levels and disease progression in astrocytic tumours. Lai N; Zhu H; Chen Y; Zhang S; Zhao X; Lin Y Folia Neuropathol; 2014; 52(1):79-85. PubMed ID: 24729345 [TBL] [Abstract][Full Text] [Related]
19. Advances in Research of Adult Gliomas. Finch A; Solomou G; Wykes V; Pohl U; Bardella C; Watts C Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477674 [TBL] [Abstract][Full Text] [Related]
20. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas. Gömöri E; Pál J; Kovács B; Dóczi T Diagn Pathol; 2012 Jan; 7():8. PubMed ID: 22264301 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]